Parkinson’s Disease Treatment Market Overview 2019-2022

Add MediaVisualText
The Parkinson’s disease treatment market was valued at USD 3.99 billion in 2016 and expected to grow at a CAGR of 6.1% from 2017 to 2022 to reach USD 5.69 billion in 2022.

Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=47265247

The major driving factors for this market include ageing population and government funding for research, growing healthcare awareness. The base year considered for the study is 2016, and the forecast has been provided for the period between 2018 and 2023.

Top Key Players

Key players operating in the Parkinson’s disease treatment market include Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), UCB (Belgium), Valeant Pharmaceuticals (Canada), Acadia (US), Sun Pharma (India), Wockhardt (India), Dr. Reddy’s (India), Intas (India), US WorldMeds (US), Zydus Cadila (India), Cipla (India), Strides (India), 1 A Pharma (India), and Upsher-Smith (US).

Major Develpoments:

  • In 2016, ACADIA Pharmaceuticals, Inc. (U.S.) received FDA approval for its NUPLAZID drug
  • In 2016, Sun Pharmaceutical Industries Ltd. (India) entered distribution agreement with Mitsubishi Tanabe Pharma Corporation (Japan) to distribute 14 prescription brands that include Parkinson’s disease drug Parlodel in Japan

he Parkinson’s disease treatment market is segmented on the basis of drug class, distribution channel, patient care setting, and region. On the basis of drug class, the market is segmented into carbidopa/levodopa, dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. The carbidopa/levodopa segment is expected to account for the largest share of the market in 2017. The growth in this segment is primarily attributed to the potency of the drug.

By distribution channel, the market is segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. In 2017, the hospital pharmacies segment accounted for the largest share of the market. Increasing number of patient visits to the hospital due to the availability of diagnostic laboratories and presence of skilled neurologists are driving the growth of hospital pharmacies segment.

On the basis of patient care setting, the Parkinson’s disease treatment market is segmented into hospitals and clinics. In 2017, hospitals are expected to account for the largest share of the market. Robust health infrastructure and presence of skilled neurologists are the driving factors for hospital segment.